Canopy Growth vs. Tilray Brands: Which Healthcare Stock Is a Better Buy in 2026?
2026-10-10 21:18
•Sarah Sidlow •The Motley Fool
•••• •• Axe Cap view
Tilray, Canopy and SA’s cautious cannabis exposure
Tilray shows stronger growth and margins, but local investors should watch the rand and regulatory risks closely.
Both Tilray and Canopy Growth remain loss-making despite solid revenue growth, reflecting how tough the cannabis sector is globally. Tilray edges Canopy with better margins and lower debt, thanks to diversification into craft beverages and wellness products. Canopy’s pure cannabis play has clarity but more regulatory headwinds, especially given U.S. states' patchy legalization progress. South African investors don't have a direct JSE cannabis play yet, so USD/ZAR swings become crucial for any forex or ADR exposure— a stronger rand generally punishes returns from these U.S.-listed names. If the rand weakens on local risks or global dollar strength, dollar-denominated losses widen here. Capitec and FirstRand show how focused domestic banking benefits from local stability, unlike these much riskier bets. Tilray’s complexity could spook investors if integration fails, while Canopy’s regulatory risks remain acute. Both are speculative, but Tilray’s model offers slight edge if you want to tiptoe into cannabis. this is just our opinion and not financial advice
Avoid direct investment in the cannabis duopoly for now; watch USD/ZAR closely for risk appetite signals. If you must, favor Tilray for better financials but prepare for volatility.
- TLRY
- CGC
- USD/ZAR
- U.S. cannabis legalization delays
- Rand volatility affecting dollar exposure
6/10
Canopy Growth and Tilray Brands represent diverging strategies in the cannabis industry. Canopy pursues a lean, brand-focused model with emphasis on U.S. expansion, while Tilray has diversified into craft beverages and wellness products. Both companies reported significant net losses in FY 2026 despite revenue growth, with Tilray showing better financial metrics (higher revenue, lower debt-to-equity ratio, higher gross margin) but greater business complexity. The article suggests Tilray may appeal to diversification-focused investors, while Canopy attracts those betting on pure cannabis growth, though both carry substantial risks.
Our take is based on reporting first published by The Motley Fool.